Literature DB >> 29907674

Feasibility of Measurement and Adherence to System Performance Measures for Rheumatoid Arthritis in 5 Models of Care.

Claire E H Barber1,2, J Carter Thorne3,4, Vandana Ahluwalia3,4, Jennifer Burt3,4, Diane Lacaille3,4, Deborah A Marshall3,4, Glen S Hazlewood3,4, Dianne Mosher3,4, Lisa Denning3,4, Ildiko Szamko3,4, Ricky Chin3,4, Sean Hamilton3,4, Susanne Benseler3,4, Marinka Twilt3,4, Natalie J Shiff3,4, Vivian Bykerk3,4, Joanne Homik3,4, Cheryl Barnabe3,4.   

Abstract

OBJECTIVE: To test the feasibility of reporting on 4 national performance measures for patients with rheumatoid arthritis (RA) in 5 different models of care.
METHODS: The following performance measures were evaluated in 5 models of care: waiting time (WT) to rheumatologist consultation, percentage of patients seen in yearly followup (FU), percentage taking disease-modifying antirheumatic drugs (DMARD), and time to starting DMARD. All models aimed to improve early access and care for patients with RA.
RESULTS: A number of feasibility issues were encountered in performance measure evaluation because of differences in site data collection and/or the duration of the model of care. For example, while 4/5 programs maintained clinical or research databases, chart reviews were still required to report on WT. Median WT for care in 2015 varied by site between 21 and 75 days. Yearly FU rates could only be calculated in 2 sites (combined owing to small numbers) and varied between 83% and 100%. Percentage of patients taking a DMARD and time to DMARD could be calculated in 3 models, and rates of DMARD use were between 90% and 100%, with median time to DMARD of 0 days in each.
CONCLUSION: Our review has shown that even in models of care designed to improve access to care and early treatment, data to document improvements are often lacking. Where data were available for measuring, deficits in WT performance were noted for some centers. Our results highlight a need to improve reporting processes to drive quality improvement.

Entities:  

Keywords:  QUALITY INDICATORS; QUALITY OF HEALTHCARE; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2018        PMID: 29907674     DOI: 10.3899/jrheum.171284

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  A Population-Based Study Evaluating Retention in Rheumatology Care Among Patients With Rheumatoid Arthritis.

Authors:  Claire E H Barber; Diane Lacaille; Ruth Croxford; Cheryl Barnabe; Deborah A Marshall; Michal Abrahamowicz; Hui Xie; J Antonio Avina-Zubieta; John M Esdaile; Glen Hazlewood; Peter Faris; Steven Katz; Paul MacMullan; Dianne Mosher; Jessica Widdifield
Journal:  ACR Open Rheumatol       Date:  2022-05-05

2.  Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care.

Authors:  Claire E H Barber; Lisa M Lix; Diane Lacaille; Deborah A Marshall; Kristine Kroeker; Susanne Benseler; Marinka Twilt; Heinrike Schmeling; Cheryl Barnabe; Glen S Hazlewood; Vivian Bykerk; Joanne Homik; J Carter Thorne; Jennifer Burt; Dianne Mosher; Steven Katz; Natalie J Shiff
Journal:  BMC Health Serv Res       Date:  2019-08-14       Impact factor: 2.655

3.  Strategies for developing and implementing a rheumatoid arthritis healthcare quality framework: a thematic analysis of perspectives from arthritis stakeholders.

Authors:  Claire Barber; Diane Lacaille; Marc Hall; Victoria Bohm; Linda C Li; Cheryl Barnabe; James Rankin; Glen Hazlewood; Deborah A Marshall; Paul Macmullan; Dianne Mosher; Joanne Homik; Kelly English; Karen Tsui; Karen L Then
Journal:  BMJ Open       Date:  2021-03-05       Impact factor: 2.692

Review 4.  A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care.

Authors:  Claire E H Barber; Marinka Twilt; Tram Pham; Gillian R Currie; Susanne Benseler; Rae S M Yeung; Michelle Batthish; Nicholas Blanchette; Jaime Guzman; Bianca Lang; Claire LeBlanc; Deborah M Levy; Christine O'Brien; Heinrike Schmeling; Gordon Soon; Lynn Spiegel; Kristi Whitney; Deborah A Marshall
Journal:  Arthritis Res Ther       Date:  2020-03-19       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.